Extract
We read the paper by Davies Forsman et al. [1] and could not agree more with their findings. The authors report that in the studied geographical area and clinical population, the dose of levofloxacin and moxifloxacin should be increased to achieve the optimal exposure target in order to effectively treat multidrug-resistant tuberculosis, and suggested therapeutic drug monitoring (TDM) to avert any adverse event [1, 2]. The target drug exposure and dose in the study were selected based on the evidence collected using pharmacokinetic/pharmacodynamic studies in both pre-clinical models and in the clinic [3].
Abstract
Fluoroquinolones at currently prescribed standard dose are suboptimal for treatment of multidrug-resistant tuberculosis. The dose should be increased with therapeutic drug monitoring to determine the drug exposure and to prevent adverse events. https://bit.ly/3nMip2Z
Footnotes
Author contributions: S. Srivastava wrote the first draft of the manuscript; both authors read the manuscript and approved the final version of the manuscript.
Conflict of interest: S. Srivastava has nothing to disclose.
Conflict of interest: T. Gumbo has nothing to disclose.
- Received November 12, 2020.
- Accepted December 16, 2020.
- ©ERS 2021.